TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3028362

Group type: EXPERIMENTAL
Intervention: Beta Interferon cream (20,000 iu/g)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30719450

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 120
Study: 27641367

Group type: EXPERIMENTAL
Intervention: Perioperative delirium
Number of subjects: 385

Group type: COMPARATOR
Intervention: No perioperative delirium
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Higher S100B levels
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Premorbid cognitive impairment
Number of subjects: 385
Study: 26111939

Group type: EXPERIMENTAL
Intervention: Centralized, web‐based cardiovascular risk service (CVRS) managed by clinical pharmacists for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 24311828

Group type: EXPERIMENTAL
Intervention: Wu-Ling-San (WLS) formula, 2 gm three times daily for 1 month
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo, 2 gm three times daily for 1 month
Number of subjects: 39
Study: 21865574

Group type: EXPERIMENTAL
Intervention: ATRA (20 mg/m²/d)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ATRA (20 mg/kg PO) in animal model
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cisplatin and Paclitaxel (control groups in animal model)
Number of subjects: 95
Study: 19659873

Group type: EXPERIMENTAL
Intervention: Oral procyanidin + vitamins A, C, E
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16626577

Group type: EXPERIMENTAL
Intervention: Rapamycin eluting stent (Cypher)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Paclitaxel eluting stent (TAXUS)
Number of subjects: 416
Study: 15182401

Group type: EXPERIMENTAL
Intervention: Composite breakfast meals
Number of subjects: 28
Study: 11843249

Group type: EXPERIMENTAL
Intervention: SIR-Spheres plus chemotherapy (HAC)
Number of subjects: 74
Study: 9684188

Group type: EXPERIMENTAL
Intervention: Oral specific hyposensitization treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7849967

Group type: EXPERIMENTAL
Intervention: Fluosol DA-20% (FDA) intravenous infusion at 30 cc/kg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no FDA treatment)
Number of subjects: 55
Study: 3370307

Group type: EXPERIMENTAL
Intervention: 14C‐DMPP with a high-fat meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3H‐DMPP with a high-fat meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: 3H‐DMPP in fasting state
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DMPP and its metabolites
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metabolites of DMPP
Number of subjects: 18
Study: 30298685

Group type: EXPERIMENTAL
Intervention: High opioid consumption trajectories
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Lowest opioid consumption trajectory
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Age and baseline levels of anxiety
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 152
Study: 29180457

Group type: EXPERIMENTAL
Intervention: β-blocker (Bbl)
Number of subjects: 1873
Study: 25343235

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary advice, coaching, and exercise during pregnancy)
Number of subjects: 157
Study: 23949839

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-based PN service
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 59
Study: 20726814

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 2617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study: 19905933

Group type: EXPERIMENTAL
Intervention: AQ-SP
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: AS-AQ
Number of subjects: 61

Group type: COMPARATOR
Intervention: AL
Number of subjects: 61
Study: 16783479

Group type: EXPERIMENTAL
Intervention: AM-24 (500 mg once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AM-24 (240 mg and 350 mg doses also administered)
Number of subjects: 24
Study: 15145629

Group type: EXPERIMENTAL
Intervention: Banked breastmilk
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Greater proportion of human milk intake in infancy
Number of subjects: 216

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 216
Study: 11283536

Group type: EXPERIMENTAL
Intervention: CoStasis Surgical Hemostat
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control (manual compression)
Number of subjects: 318
Study: 9060084

Group type: EXPERIMENTAL
Intervention: Retropubic urethrocystopexy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pubococcygeal repair
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined surgical techniques (treated as one group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Improved/Failure group (one year after surgery)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cured women
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Predictors of surgical outcome
Number of subjects: 45
Study: 8445423

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus fenretinide 100, 200, 300, or 400 mg/d
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tamoxifen plus fenretinide
Number of subjects: 15
Study: 2429008

Group type: EXPERIMENTAL
Intervention: Cordarone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ethmosine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mexitil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rhytmilen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Finoptin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 80
Study: 31613432

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual oxygen therapy
Number of subjects: 1000
Study: 29861249

Group type: EXPERIMENTAL
Intervention: Zumba dancing performed twice a week for 12 weeks
Number of subjects: 19
Study: 26787201

Group type: EXPERIMENTAL
Intervention: Individualised case management with a personalised booklet ('Passport') and up to four brief telephone contacts in the first 4 weeks post-release
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1325

Group type: EXPERIMENTAL
Intervention: Individualised case management
Number of subjects: 1325
Study: 25711324

Group type: EXPERIMENTAL
Intervention: CKD prevalence among ART-naïve adults
Number of subjects: 4637

Group type: EXPERIMENTAL
Intervention: Urine protein ≥ 1+
Number of subjects: 4637

Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73 m²
Number of subjects: 4637

Group type: EXPERIMENTAL
Intervention: Baseline characteristics associated with CKD
Number of subjects: 4637
Study: 23902955

Group type: EXPERIMENTAL
Intervention: PDF (per 100 mL: 67 kcal, 1.7 g protein, 65 mg calcium, 38 mg phosphorus, 56 IU vitamin D)
Number of subjects: 139

Group type: COMPARATOR
Intervention: TF (per 100 mL: 67 kcal, 1.47 g protein, 50 mg calcium, 30 mg phosphorus, 48 IU vitamin D)
Number of subjects: 139

Group type: COMPARATOR
Intervention: HM
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: PDF
Number of subjects: 139
Study: 21917892

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine (ABC/3TC) with efavirenz (EFV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine (ABC/3TC) with atazanavir/ritonavir (ATV/r)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenofovir DF/emtricitabine (TDF/FTC) with atazanavir/ritonavir (ATV/r)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine (ABC/3TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenofovir DF/emtricitabine (TDF/FTC)
Number of subjects: 0
Study: 18946504

Group type: EXPERIMENTAL
Intervention: Upright images of faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inverted images of faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upright images of houses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inverted images of houses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upright images of bodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inverted images of bodies
Number of subjects: 0
Study: 17165299

Group type: EXPERIMENTAL
Intervention: Silicone-based resilient denture liner (SR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin (AR)
Number of subjects: 28
Study: 14708472

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pantoprazole 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Basal (no treatment)
Number of subjects: 10
Study: 11062278

Group type: EXPERIMENTAL
Intervention: Acute stroke unit care integrated with geriatric stroke unit care continuum
Number of subjects: 249

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 249
Study: 9709269

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study: 8269207

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 84
Study: 3623787

Group type: EXPERIMENTAL
Intervention: Reinfusion of autologous blood (1350 ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (six well‐trained skiers)
Number of subjects: 6
Study: 31691053

Group type: EXPERIMENTAL
Intervention: Diode laser (G3, n = 25), 400 mW, continuous mode, 5 s per point, 23 points, total energy per session 46 J
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ozone therapy (G2, n = 26), generator probe type 3, working time per point 5 s, 23 points, application time 1 min and 55 s
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (G1, n = 26)
Number of subjects: 76
Study: 29590338

Group type: EXPERIMENTAL
Intervention: Role-focused self-help course (n = 65)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Wait list control (n = 63)
Number of subjects: 128
Study: 28637773

Group type: EXPERIMENTAL
Intervention: Postdischarge formula (PDF)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Term formula (TF)
Number of subjects: 79
Study: 25704754

Group type: EXPERIMENTAL
Intervention: Integrated computer-based procedure (CBP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Existing individual computer-based procedure (CBP)
Number of subjects: 60
Study: 24139003

Group type: EXPERIMENTAL
Intervention: Combined pressure release and 10 s passive stretch
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study: 21118369

Group type: EXPERIMENTAL
Intervention: HA330 hemoperfusion treatment (N=24)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard therapy (N=20)
Number of subjects: 44
Study: 18230016

Group type: EXPERIMENTAL
Intervention: Breast symptoms and greater cancer worry
Number of subjects: 3758

Group type: EXPERIMENTAL
Intervention: Random change
Number of subjects: 3758
Study: 16630748

Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 14600520

Group type: EXPERIMENTAL
Intervention: TMC125 (900 mg twice daily for 7 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 14675010

Group type: EXPERIMENTAL
Intervention: Unipolar LV from the cardiac venous lead
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bipolar LV using the tip electrode in the cardiac vein as the cathode and the ring electrode of the RV lead as the anode
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bipolar RV from the RV lead
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Unipolar split cathodal stimulation of the cardiac venous and RV leads
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bipolar split cathodal stimulation of the cardiac venous and RV leads
Number of subjects: 19
Study: 10080589

Group type: EXPERIMENTAL
Intervention: Capecitabine at 2,510 mg/m2/d for 2 weeks followed by a 1-week rest period, repeated in 3-week cycles.
Number of subjects: 163
Study: 7813270

Group type: EXPERIMENTAL
Intervention: Aerosolized norepinephrine (NE) 0.04 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 1763589

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg bolus followed by 5 mg infusion over 1 h) + TENS (low or high frequency)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxycodone (5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Buprenorphine (0.15 mg)
Number of subjects: 60
Study: 6410971

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) 1 mg intravenously as a bolus dose, followed by 1 mg infused over 5 minutes, then 1 mg intravenously every 12 hours for 3 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 13
Study: 3966338

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study: 28960164

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI) delivered by a supervised sleep educator
Number of subjects: 159

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 159
Study: 27329400

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg, 3 times a day for 16 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26194932

Group type: EXPERIMENTAL
Intervention: Isocapnic voluntary hyperpnea to task failure (FT+)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study: 23873891

Group type: EXPERIMENTAL
Intervention: Bimatoprost ophthalmic solution 0.03%
Number of subjects: 278

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 278
Study: 21914755

Group type: COMPARATOR
Intervention: Sham group (2 mL 0.9% saline)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Epidural saline group (30 mL 0.9% saline)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Epidural steroid group (40 mg triamcinolone acetonide in 29 mL 0.9% saline)
Number of subjects: 133
Study: 19052125

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a at a dosage of 90 microg per week for 3.5 years
Number of subjects: 1050

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1050
Study: 16801668

Group type: EXPERIMENTAL
Intervention: Folate 1 mg/vitamin B(12) 500 microg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12925824

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Human dentine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bovine dentine
Number of subjects: 11
Study: 11061655

Group type: EXPERIMENTAL
Intervention: Standard dose therapy with zidovudine, lamivudine, and indinavir
Number of subjects: 8
Study: 9357394

Group type: EXPERIMENTAL
Intervention: 80 mg seratrodast
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 120 mg seratrodast
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 8260471

Group type: EXPERIMENTAL
Intervention: 0.3 g protein/kg per d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.4 g protein/kg per d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 g protein/kg per d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.6 g protein/kg per d
Number of subjects: 12
Study: 2877759

Group type: EXPERIMENTAL
Intervention: Phenacetin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (water diuresis)
Number of subjects: 5
Study: 31626990

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg every 4 weeks for 52 weeks
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 953

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 953
Study: 29263226

Group type: EXPERIMENTAL
Intervention: Adult definition of silent cerebral infarct (T2-weighted hyperintensity ≥5 mm with corresponding T1-weighted hypointensity on MRI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Reference pediatric definition of silent cerebral infarct (T2-weighted hyperintensity ≥3 mm on MRI)
Number of subjects: 150
Study: 26860802

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment (herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21), Chinese acupoint application (d1-d21))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed (500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8))
Number of subjects: 64
Study: 24992975

Group type: EXPERIMENTAL
Intervention: First diagnosis
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Minor discrepancy
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Major discrepancy
Number of subjects: 454
Study: 22867511

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: General psychiatric management
Number of subjects: 87
Study: 20829132

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZM) preparation 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZM) preparation 2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Internal standard (omeprazole)
Number of subjects: 24
Study: 18937894

Group type: EXPERIMENTAL
Intervention: Soluble dietary fiber (including psyllium, beta-glucan, pectin, and guar gum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soluble fiber from legumes and vegetables
Number of subjects: 0
Study: 16866719

Group type: EXPERIMENTAL
Intervention: Topiramate (mean dose 124.7 mg/d)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Topiramate (open-label extension phase only)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Topiramate (double-blind phase)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo (double-blind phase)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Topiramate (open-label extension phase)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo (open-label extension phase)
Number of subjects: 567
Study: 12811613

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) - Group T; n=20
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infrared lasertherapy - Group L; n=20
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture - Group A; n=20
Number of subjects: 60
Study: 10743866

Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel applied during periodontal surgery
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Surgery only
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Surgery + 25% metronidazole gel
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (healthy untreated sites)
Number of subjects: 43
Study: 9184738

Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg tablets/2 mg dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg tablets/8 mg dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg tablets/10 mg dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1524898

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) - lumpectomy, axillary clearance, and radiotherapy (50 Gy in 5 weeks external irradiation and a boost with iridium implant of 25 Gy)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Radical mastectomy (RM)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Salvage treatment for local recurrence
Number of subjects: 902
Study: 4050648

Group type: EXPERIMENTAL
Intervention: Continuous wave Doppler echocardiography
Number of subjects: 60
Study: 31356921

Group type: EXPERIMENTAL
Intervention: ASN002 (20 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ASN002 (40 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ASN002 (80 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29301124

Group type: EXPERIMENTAL
Intervention: Iron-denatured whey protein (Iron-WP) microspheres
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 21
Study: 26259770

Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of 100×10(6) autologous bone marrow mononuclear cells
Number of subjects: 23
Study: 23329566

Group type: EXPERIMENTAL
Intervention: Health facilities with adequate staffing and availability of medical equipment and medications
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Health facilities performing cesarean sections
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Availability of oxygen in hospitals
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Availability of blood in hospitals
Number of subjects: 364
Study: 21521310

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg and cholecalciferol 5600 IU (RSD+)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Risedronate 35 mg alone (RSD)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study: 18645245

Group type: EXPERIMENTAL
Intervention: Q10Vital liquid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Q10Vital powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soft-gel capsules with CoQ10 in soybean oil (reference)
Number of subjects: 0
Study: 16155071

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 microg every 3 h for a maximum of three doses)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Extended course of sublingual misoprostol (400 microg daily for 1 week)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Extended course of sublingual misoprostol
Number of subjects: 180